cas 627-11-2|| where to buy 2-Chloroethyl chloroformate

Название продукции:2-Chloroethyl chloroformate

IUPAC Name:2-chloroethyl carbonochloridate

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM383952-500g	1-2 Weeks	ƿƃ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 627-11-2 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:627-11-2; Молекулярная формула:C3H4Cl2O2; Точка плавления:-; Smiles-код:ClCCOC(Cl)=O; Плотность:

: Номер в каталоге:CM383952; Молекулярная масса:142.96; Точка кипения:; Номер Mdl:; Хранение:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Erdafitinib; The Janssen Pharmaceutical Companies of Johnson & Johnson announced on September 8, 2023, that it had submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) to seek approval of Erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, with disease progression during or following at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-[L]1) inhibitor.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.